N
News Analysis
prnewswire.com

www.prnewswire.com ·

Negative

Hyundai Bioscience Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread

AffectInfectious DiseaseCommunicable DiseaseInfectious

All NewsRead the full story on prnewswire.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

The announcement is a preparedness statement with no immediate commercial mechanism. No orders, contracts, or revenue impact are specified. The company can supply from current stock if requested by WHO or affected countries. The commercial mechanism is weak and contingent on future outbreak response.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Hyundai Bioscience can supply clinical trial doses of XAFTY® for Ebola and hantavirus.
  • XAFTY® contains niclosamide, which has shown inhibitory effects against both viruses.
  • The drug is in Phase 2 clinical trial for dengue fever in Vietnam.
  • Hyundai Bioscience is a member of the Medical CBRN Defense Consortium.
  • No adverse events reported in the dengue trial.

About the publisher

prnewswire.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

prnewswire.com files this story under "affect" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Hyundai Bioscience Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread — News Analysis